Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma: a multi-institutional retrospective study.
Ryo MiyataMasatsugu HamajiAtsushi KawaguchiYumeta ShimazuMasaki IkedaMasashi IshikawaHidenao KayawakeToshi MenjuMasashi KobayashiNorihito OkumuraYasuto SakaguchiMakoto SonobeAkira MatsumotoTsuyoshi ShojiHiromichi KatakuraRyota SumitomoCheng-Long HuangMamoru TakahashiAkihiro AoyamaYusuke MuranishiTomoya KonoRyo MiyaharaNaoki DateTakuji FujinagaEi MiyamotoTatsuo NakagawaTakahisa FukadaHiroaki SakaiHiroshi DatePublished in: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2022)
First-line EGFR-TKI treatment was generally associated with favourable survival outcomes in patients with postoperative recurrent EGFR-mutated lung adenocarcinoma. EGFR ex 21 L858R mutation may be an important prognostic factor for shorter PFS.